Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

@article{Soria2015GefitinibPC,
  title={Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.},
  author={Jean – Charles Soria and Yi-Long Wu and Kazuhiko Nakagawa and S Kim and Jinji Yang and Myung-Ju Ahn and Jie Wang and James C Yang and You Lu and Shinji Atagi and Santiago Ponce and Dae Ho Lee and Yunpeng Liu and Kiyotaka Yoh and Jianying Zhou and Xiao-jin Shi and Alan Webster and Haiyi Jiang and Tony Shu Kam Mok},
  journal={The Lancet. Oncology},
  year={2015},
  volume={16 8},
  pages={990-8}
}
BACKGROUND Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. METHODS The randomised, phase 3, multicentre IMPRESS study was done in 71 centres in 11… CONTINUE READING